Reversed Micellar Fractionation of Recombinant-DNA Therapeutic Protein Intermediates

重组 DNA 治疗性蛋白质中间体的反胶束分级分离

• 批准号: 9160618
• 负责人: Trevor Castor
• 金额: $ 5万
• 依托单位: Aphios Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-03-15 至 1992-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9160618&HistoricalAwards=false
• 关键词: Reversed; Micellar; Fractionation; Recombinant; DNA

Bio-Eng is developing a continuous flow reversed micellar-organic phase (RM-ORG) process for the initial fractionation or purification of recombinant-DNA therapeutic protein intermediates which are harvested from a fermentation broth. The proposed RM-ORG process will not compete with, but will rather complement high resolution chromatographic purification steps. RM-ORG fractionation would increase throughput capacity by reducing the loading on higher resolution chromatographic purification steps, and would thus reduce production time and costs. Modest to high improvements in specificity (2 to 10 fold) and high yields (95 to 100%) are anticipated. Other intrinsic benefits to the RM-ORG process such as process stream clarification, concentration and buffer exchange are also anticipated. Potential advantages of RM-ORG over existing primary purification processes include selectivity, speed of processing, preservation of protein integrity, and scalability.

Bio-Eng正在开发一种连续流动反向 最初的胶束有机相（RM-ORG）工艺 重组DNA的分级分离或纯化 治疗性蛋白质中间体， 发酵液。 拟议的RM-ORG进程将 不是竞争，而是互补 分离色谱纯化步骤。 RM-ORG 分馏将增加生产能力， 降低高分辨率色谱上的负载 纯化步骤，从而减少生产时间 和成本。 特异性中度至高度改善（2 到10倍）和高产率（95 - 100%）。 RM-ORG工艺的其他固有优点，例如 工艺流澄清、浓缩和缓冲 交换也在预料之中。 潜在优势 RM-ORG优于现有初级纯化工艺 包括选择性、处理速度、保存 蛋白质完整性和可扩展性。